This phase III trial is trying to determine the effect of an oral chemotherapy (Cabozantinib) in patients with Differentiated Thyroid Cancer who have progressed on prior targeted treatment.
This trial is treating patients with differentiated thyroid cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy
Eligible patients will be randomised in a 2:1 ratio to receive either cabozantinib or placebo. All patients will receive oral tablets containing 60-mg or 20-mg cabozantinib or placebo equivalent once daily.
Recruiting Hospitals Read More